With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

Autoimmunity: Flu Shots Work for Patients on TNF-Inhibitors
TNF inhibitors reduce response to influenza vaccination, but about 80% of RA patients still develop protective titers after a single vaccine dose...

Arthritis: Strontium Ranelate May Slow Osteoarthritis Progression
The osteoporosis drug strontium ranelate (Protelos) may stop or slow the progression of osteoarthritis (OA) and also might alleviate back pain...

BioPharm Business: Manhattan Pharmaceuticals Initiates Phase IIa Study of Topical PTH (1-34) for Psoriasis
Manhattan Pharmaceuticals, Inc, a pharmaceutical company that acquires and develops drug candidates primarily for the treatment of dermatologic and immunologic disorders, announced that the first patient has received the initial dose of topical PTH (1-34) in a US multicenter, randomized, double-blind, vehicle-controlled, parallel group, phase IIa psoriasis study...

Arthritis: Lab-on-a-Chip Promises Fast Profile of RA Patients' Autoantibodies
A new technique promises fast, inexpensive serum antibody profiling in RA patients without the need for fluorescent labeling or preprocessing...

BioPharm Business: Cytokine PharmaSciences Develops Orally Active Form of Semapimod, a Raf Kinase Inhibitor, for Inflammatory and Autoimmune Diseases; Seeks Partner
Cytokine PharmaSciences Inc, a privately-held, global biopharmaceutical company, announced development of an orally active form of semapimod, its anti-inflammatory cytokine compound...

To remove your e- mail address from our mailing list, please send a blank email to . For questions and comments regarding this newsletter please contact